

5. Literaturverzeichnis

1. AALTOMAA S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjänen K: Prognostic factors after 5 years follow-up in female breast cancer. *Oncology* 1992, 49: 93-98
2. AALTOMAA S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjänen K: Histological assessment of the prognostic factors in female breast cancer. *Oncology* 1992, 49:1-8
3. AALTOMAA S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjänen K: Tumor size, nuclear morphometry, mitotic indices as prognostic factors in axillary-lymph- node-positive breast cancer. *Eur Surg Res* 1992, 24: 160-168
4. AALTOMAA S, Lipponen P, Papinaho S, Syrjänen K: Proliferating-cell nuclear antigen (PC10) immunolabeling and other proliferation indices as prognostic factors in breast cancer. *J Cancer Res Clin Oncol* 1993, 119(5): 288-94
5. AALTONEN M, Lipponen P, Kosma VM, Aaltomaa S, Syrjänen K: Prognostic value of cathepsin-D expression in female breast cancer. *Anticancer Res* 1995, May-Jun 15(3): 1033-7
6. ADAMI, H-O: Breast cancer incidence and mortality. Aspects on etiology, time, trends and curability. *Acta Chir Scand* 1984, 519: 9-14
7. ADAMI H-O, Bergstrom R, Hansen J: Age at first primary as a determinant of the incidence of bilateral breast cancer: Cumulative and relative risks in a population-based case-control study. *Cancer* 1985, 55: 643-647
8. AEBERHARD P: Beeinflußt die chirurg. Technik die Häufigkeit des Lokalrezidivs nach Mastektomie ? *Helv chir Acta* 1992, 59:147-156
9. AHR A, Scharl A, Gohring UJ, Crombach G, Stoffl M: Immunhistochemischer Nachweis des pS2-Proteins an Paraffinschnitten von Mamma-karzinomgeweben. Vergleich mit den Ergebnissen eines immunoradiometrischen Assays. *Pathologie* 1995, Jul 16(4): 278-84
10. ALDERSON MR, Hamlin I, Staunton MD: The relative significance of prognostic factors in breast carcinoma. *Br J Cancer* 1971, 25:646-656
11. ARRIAGADA R, Rutqvist LE, Skoog L, Johansson H, Kramar A: Prognostic factors and natural history in lymph node-negative breast cancer patient. *Breast Cancer Res Treat* 1992, 21:101-109

12. ATKINSON EN, Brown BW, Montague ED:
Tumor volume, nodal status and metastasis in breast cancer in women.
JNCI 1986,76:171-178
13. AXELSSON ChK, Mouridsen HT, Zedeler K:
Axillary dissection of Level I and II Lymph nodes is important in breast cancer classification.
Eur J Cancer 1992, Vol. 28A No. 8/9: 1415-1418
14. BAAK JPA, van Dop H, Kurver PHJ:
The value of morphometry to classic prognosticators in breast cancer.
Cancer 1985, 56: 374-382
15. BÄSSLER, R.:
Mamma. In: REMMELE, W. (Hrsg.): Pathologie. Bd.4.2.Aufl.
Springer-Verlag, Berlin, Heidelberg, New York (1997). S.242
16. BÄSSLER R, Böcker W, Hermanek P, Pickartz H, Prechtel P, Schauer A Schnürch HG und Stegner HE:
Die gegenwärtige Situation beim Mammakarzinom.
Pathologie 1992, 13:130-134
17. BÄSSLER R, HG Schnürch:
Standards der pathohistologischen Aufarbeitung des Mammakarzinoms. Ein Beitrag zur Qualitätssicherung in Pathologie und Klinik.
Gynäkologie 1994, 27:23-36
18. BERG JW:
Morphological evidence for immune response to cancer-an histological review.
Cancer 1991, 28:143-147
19. BESSE G, Kwiatkowski F, Gaillard G, Daver A, Dalifard I, Basuyau JP, Brunelle P, Wafflard J, Angibeau RM, Auvray E:
Role pronostique de la proteine pS2 dans 1065 cas de cancer du sein. Etude multi-centrique.
Bull Cancer 1994 Apr, 81(4):289-96
20. BETTA PG, Bottero G, Pavesi M, Pastormerlo M, Bellinger D, Tallarida F:
Cell proliferation in breast carcinoma assessed by a PCNA grading system and its relation to other prognostic variables.
Surg Oncol 1993, 2(1): 59-63
21. BETTELHEIM R, Penmann HG, Thornton-Jones H, Neville AM:
Prognostic significans of peritumoral vascular invasion in breast cancer.
Cancer 1984, 50: 771-777
22. BEVILACQUA P, Barbareschi M, Verderio P, Boracchi P, Caffo O, Dalla-Palma P, Meli S, Weidner N, Gasparini G:
Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma-results of a multiparametric study.
Breast Cancer Res Treat 1995, 36(2): 205-17

23. BIANCHI S, Paglierani M, Zampi G, Cardona G, Cataliotti L, Bonardi R, Zappa M, Ciatto S:
Prognostic value of proliferating cell nuclear antigen in lymph node-negative breast cancer patients.
Cancer 1993 Jul 1, 72(1): 120-5
24. BILIK R, Mor C, Wolloch Y, Dintsmen M:
Histopathologic high risk factors influencing the prognosis of patients with early breast cancer (T1N0M0).
Am J Surg 1986,151/4:460-464
25. BINDER C, Marx D, Overhoff R, Binder L, Schauer A, Hiddemann W:
Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables.
Ann Oncol 1995 Dec, 6(10): 1005-10
26. BLACK MM, Opler SR:
Survival in breast cancer cases in relation to structure of the primary tumor and regional lymph nodes.
Surg Gynecol Obstet 1955, 100:543-551
27. BLACK MM, Barclay THC, Hankey BF:
Prognosis in breast cancer utilizing histologic characteristics of the primary tumor.
Cancer 1975, 25: 2048-2055
28. BLISS P, Fisker J, Roulsten J, Leonard RC:
An assessment of the clinical usefulness of two serum markers, CA15 3 and HMFG 2 in localized and metastatic breast cancer.
Dis-Markers 1993 Jun, 11(1):45-8
29. BLOOM HJG, Richardson WW:
Histological grading and prognosis in breast cancer.
Br J Cancer 1975,11: 359-377
30. BLOOM HLG, Richardson WW, Fields JR:
Host resistance and survival in carcinoma of breast: A study of 104 cases of medullary carcinoma in a series of 1411 cases of breast cancer followed for 20 years.
Br Med J 1970, 3:181-188
31. BONNIER P, Romain S, Charpin C, Lejeune Ch, Tubiana N, Martin PM, Piana, L:
Age as a prognostic factor in breast cancer: Relationship to pathologic and biologic features.
Int J Cancer 1995, 62:138-144
32. BOSARI S, Lee AK, Tahan SR, Figoni MA, Wiley BD, Heatly GJ, Silverman ML:
DNA flow cytometric analysis and prognosis of axillary lymph node-negative breast carcinoma.
Cancer 1992, 70:1943-1950
33. BORGER J, Kempermann H, Hart A, Peterse H, Dongen van J, Bartelink H:
Risk factors in breast-conservation therapy.
J Clin Oncol 1994, Vol 12 No 4: 653-660

34. BRENNER H, Wiebelt H, Ziegler H:
Die Entwicklung der Inzidenz und Prognose des Mamma-Karzinoms bei jungen Frauen vor dem Hintergrund von Veränderungen des Risikofaktorenprofils.
Geburtsh Frauenheilkd 1990, 50: 683-688
35. BROCKMANN B, Reitzing P:
„Prognosefaktoren“ des Mammakarzinoms - Teil 1.
Z ärztl Fortbild 1994, 88: 111-114
36. BUSSEN S, Rempen A, Caffier H:
Der prognostische Aussagewert der Cathepsin D-Konzentration im Zytosol beim primären Mammakarzinom.
Zentralbl Gynäkol 1995, 117(5): 253-259
37. CALEFFI M, Fentiman IS, Birkhead BG:
Factors at presentation influencing the prognosis in breast cancer.
Eur J Cancer Clin Oncol 1989, Vol 25 No 1: 51-56
38. CARDONE A, Tolino A, Zarcone R, Borruto Caracciolo G, Tartaglia E:
Prognostic value of desmoplastic reaction and lymphocytic infiltration in the management of breast cancer.
PANMINERVA MED 1997,39:174-177
39. CARLOMAGNO Ch, Perrone F, Lauria R, Laurentiis De M, Gallo C, Morabito A, Pettinato G, Panico L, Bellelli T, Apicella A, Petrella G, Bianco AR, Placido De S:
Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer.
Oncology 1995, 52: 272-277
40. CASCINELLI N, Greco M, Bufalino R, Clemente C, Galluzzo D, Delle Donne V, De Lellis R, Sacchini V, Veronesi U:
Prognosis of breast cancer with axillary node metastases after surgical treatment only.
Eur J Cancer Clin Oncol 1987, Vol. 23, No. 6: 795-799
41. CARTER D, Pipkin RD, Shepard RH:
Relationship of necrosis and tumor border to lymph node metastases and 10-year survival in carcinoma of the breast.
Am J Surg Pathol 1978,2:39-46
42. CARTER ChL, Allen C, Henson DE:
Relation of tumor size, lymph node status, and survival in 24.740 breast cancer cases.
Cancer 1989, 63: 181-187
43. CERRA M, Cecco L, Montella M, Tuccillo F, Bonelli P, Botti G:
Epidermal growth factor receptor in human breast cancer comparison with steroid receptors and other prognostic factors.
Int J Biol Markers 1995, Jul-Sep 10(3):136-42
44. CHUNG M, Chang HR, Bland KI, Wanebo HJ:
Younger women with breast carcinoma have a poorer prognosis the older women.
Cancer 1996, 77: 97-103

45. CLAYTON F, Hopkins ChL:
Pathologic correlates of prognosis in lymph node-positive breast Carcinomas.
Cancer 1993, 71:1780-1790
46. COLLAN YU, Eskelinen MJ, Nordling SA, Lipponen P, Pesonen E, Kumpusalo, LM,
Pajarinen P, Kettunen KO:
Prognostic studies in breast cancer.
Acta Oncologica 1994, Vol. 33, No.8: 873-878
47. CORNELISSE CJ, Velde CJ van de, Caspers RJ, Moolenaar AJ, Hermans J:
DNA ploidy and survival in breast cancer patients.
Cytometry 1987, 8: 225-234
48. CORREALE M, Paradiso A, Abbate I, Mangia A, Dragone CD, Tedone T, Filotico R,
Schittulli F, DeLena M:
Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with
tumor proliferative activity.
Tumour Biol 1993, 14(1): 30-7
49. DALTON LW, Page DL, Dupont WD:
Histologic grading of breast carcinoma. A reproducibility study.
Cancer 1994, 73: 2765-2770
50. DAVIS BW, Gelber R, Goldhirsch A, Hartmann WH, Hollaway L, Russel I,
Rudenstamm CM:
Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy
for breast cancer with axillary lymph node metastasis.
Hum Pathol 1985, 16: 1212-1218
51. DAVIS BW, Gelber R, Goldhirsch A, Hartmann WH:
Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast
cancer with axillary lymph-node metastasis.
Cancer 1986, 58/12 :2662-2670
52. DAWKINS JHS, Robbins PD, Smith KL:
What's new in breast cancer ? Molecular perspectives of cancer development and the
role of the oncogene c-erb B2 in prognosis and disease.
Pathol Res Pract 1993, 189:1233-1252
53. DAWSON PJ, Ferguson DJ, Karrison T:
The pathologic findings of breast cancer in patient surviving 25 years after radical
mastectomy.
Cancer 1982, 50: 2131-2138
54. DE MASCAREL P, Bonichon F, Coindre JM, Trojani M:
Prognostic significance of breast cancer axillary lymph node micrometastases assessed
by two special techniques: reevaluation with longer follow-up.
Br J Cancer 1992, 66: 523-527

55. DIVISION OF EPIDEMIOLOGY, NEW YORK:
Time trends in breast cancer incidence.
N.Y. State J Med. 1990, 90: 473-474
56. DOOKERAN KA, Rye PD, Dearing SJ, Walker RA:
Expression of the pS2 peptide in primary breast carcinomas: comparison of membrane and cytoplasmic staining patterns.
J Pathol 1993, Oct 171(2): 123-9
57. DOUGLAS-JONES AG, Schmid KW, Bier B, Horgan K, Lyons K, Dallimore ND, Moneypenny IJ, Jasani B:
Metallothionein expression in duct carcinoma in situ of the breast.
Hum Pathol 1995, Feb 26(2): 217-22
58. EIDTMANN H, Jonat W, Lange C, Friedrichs K, Maass H:
Krankheitsverlauf bei 551 Patientinnen mit nodal negativem Mammakarzinom.
Geburtsh Frauenheilkd 1992, 52: 454-461
59. ELLIS IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW:
Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up.
Histopathology 1992, 20: 479-489
60. ELSTON CW, Ellis IO:
Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: Experience from a large study with long-term follow up.
Histopathology 1991, 19:403-410
61. ENGELHARDT Ch, Sauerland C, Bettges G:
Beobachtung einer Zunahme „aggressiver Tumorformen“ bei ansteigender Häufigkeit des Mammakarzinoms.
Geburtsh Frauenheilkd 1996, 56:124-127
62. ESTEBAU JM, Wari Z, Mitsaru H:
Detection of intratumoral aromatase in breast carcinoma: A immunohistochemical study with clinicopathologic correlation.
Am J Pathol 1992, 140:337-343
63. FALKSON G, Gelman RS, Pretorius JF:
Age as prognostic factor in recurrent breast cancer.
J Clin Oncol 1986, 4:663-671
64. FENTIMAN IS, Hyland D, Chaudary MA, Gregory WM:
Prognosis of patient with breast cancers up to 1cm in diameter.
Eur J Cancer 1996, Vol. 32A, No. 3: 417-420
65. FISHER B, Slack NH, Bross DJ:
Cancer of the breast: Size of neoplasm and prognosis.
Cancer 1969, Vol. 24: 1071-1080

66. FISHER B, Slack NH, Ausman RK, Bross IDJ:
Location of breast carcinoma and prognosis.
Surg Gynecol Obst 1969, Oct: 705-715
67. FISCHER B, Bauer M, Wickerham L, Redmond C, Fischer ER:
Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer.
Cancer 1983, 52: 1551-1557
68. FISCHER ER, Sass R, Fischer B:
Pathologic findings from the national surgical adjuvant breast project for breast cancer (protocol no. 4).
Cancer 1984, 53: 712-723
69. FISHER ER:
Prognostic and therapeutic significance of pathological features of breast cancer.
Natl Cancer Inst 1986,1:29-34
70. FISHER ER, Palekar AS, Gregorio RM, Redmond C, Fisher B:
Pathological Findings from the national surgical adjuvant breast project (protocol No. 4). IV. Significance of Tumor necrosis.
Human Pathology 1978, Vol 9 No 5: 523-530
71. FOEKENS JA, van-Putten WL, Portengen H, de-Koning HY, Thirion B, Alexieva-Figusch J, Klijn-JG:
Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.
J Clin Oncol 1993, May 11(5): 899-908
72. FOUNTZILAS G, Vasilaros S, Koukouras D, Malamos N, Pectasides D, Adamou A, Nenopoulou E, Kiriakou K, Zouvani I, Katsolis K, Kappas A, Skopa Ch, Semoglou Ch, Fahantidis E, Konstantaras Ch, Vasilaki E, Economopoulos T, Bacoyiannis H, Bafaloukos D, Razi E, Polichronis A, Androulakis G, Papaioannou T, Pavlidis N, Skarlos D, Kosmidis P:
Prognostic variables in greek patients with stage II breast cancer: A hellenic cooperative oncology group study.
Anticancer Research 1997,17: 4681-4690
73. FRIEDMAN S, Bertin F, Mouriesse H, Bechabat A, Genin J, Sarazin D, Contesso G:
Importance of tumor cells in axillary node sinus margins ("clandestine" metastases) discovered by serial sectioning in operable breast carcinoma.
Acta Ocol (Sweden) 1988,27:483-487
74. FUNKE I, Classen M, Eiermann G:
Prognosefaktoren beim primären Mammakarzinom. In: Schriftenreihe des Tumorzentrum München mit Empfehlungen zur Diagnostik, Therapie und Nachsorge onkologischer Erkrankungen. Mammakarzinome.
Hrsg. H.Sauer 7.Aufl. 1998: S.34

75. FUNKE I, Schraut W:
Metaanalysis of studies on bone marrow micrometastases : an independent prognostic impact remains to be substantiated.
J Clin Oncol 1998, 16:557-566
76. GAGLIA P, Bussone R, Caldarola B, Lai M, Jayme A, Caldarola L:
The correlation between the spread of metastases by level in the axillary nodes and disease-free survival in breast cancer. A multifactorial analysis.
Eur J Cancer Clin Oncol, 1987, Vol 23 No 6: 849-854
77. GALLAGER HS:
Pathologic types of breast cancer: their prognosis.
Cancer 1984, 53:623-629
78. GAMEL JW, Meyer JS, Feuer E, Miller BA:
The impact of stage an histology on the long-term clinical course of 163, 808 patients with breast carcinoma.
Cancer 1996 April 15, Vol 77 No 8:1459-1464
79. GASPARINI G, Boracchi P, Bevilacqua P:
Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry.
Int J Cancer (1994), 57: 822-829
80. GASPARINI G, Boracchi P, Bevilacqua P, Mezzetti M, Pozza F, Weidner N:
A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma.
Breast Cancer Res Treat 1994 Jan, 29(1): 59-71
81. GASPARINI G, Boracchi P, Verderio P, Bevilacqua P:
Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry.
Int J Cancer 1994 Jun 15, 57(6): 822-829
82. GASPARINI G, Barbareschi M, Boracchi P, Bevilacqua P, Verderio P, Dalla-Palma P, Menard S:
67-kDa laminin-receptor expression adds prognostic information to intratumoral microvessel density in node-negative breast cancer.
Int J Cancer 1995 Mar 3, 60(5): 604-10
83. GILCHRIST KW, Gray R, Fowble B, Tormey DC, Taylor SG:
Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: A 10-year follow-up study of 728 eastern cooperative oncology group patients.
J Clin Oncol 1993, Vol 11 No 10:1929-1935
84. GION M, Mione R, Pappagallo GL, Gatti C, Nascimben O, Bari M, Leon AE, Vinante O, Brusca G:
PS2 in breast cancer-alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
Br J Cancer 1993 Aug, 68(2):374-9

85. GIOVAGNOLI MR, Reale G, Cosentino L, Manna A, Midulla C, Marchei G, Vecchione A:
Evaluation of the expression of tissue DF-3 and MCA and the corresponding serum values in patients with breast carcinoma.
Int J Biol Markers 1994 Jul-Sep, 9(3):140-144
86. GIULIANO AE, Barth AM, Spivack B, Beitsch PD, Evans SW:
Incidence and predictors of axillary metastasis in T1 carcinoma of the breast.
J Am Coll Surg Vol. 183, No. 3 (Sept.1996):185-189
87. GNANT MF, Blijham G, Reiner A, Reiner G, Reynders M, Schutte B, Asche C van, Steger G, Jakesz R:
DNA ploidy and other results of DNA flow- cytometry as prognostic factors in operable breast cancer : 10 year results of a randomised study.
Eur J Cancer 1992, 28: 711-716
88. GOHRING UJ, Schar A, Thelen U, Ahr A, Titius BR:
Der prognostische Wert der immunhistochemischen Bestimmung des Urokinase-Plasminogen-Aktivators (uPA) in primären Mammakarzinomen.
Pathologie 1995 Nov; 16(6): 398-403
89. GOLDSTEIN LJ, Galski H, Fojo A:
Expression of a multidrug resistance gene in human breast cancer.
J Natl Cancer Inst 1989, 81:116-124
90. GORCZYCA W, Holm R , Nesland JM:
Laminin production and fibronectin immunoreactivity in breast carcinomas.
Anticancer-Res 1993 Jul-Aug; 13(4): 851-8
91. GORCZYCA W, Markiewski M, Kram A, Tuziak T, Domagala W:
Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction.
Virchows Arch 1995, 426(3): 229-33
92. HAERSLEV T, Jacobsen K, Nedergaard L, Zedeler K:
Immunohistochemical detection of metallothionein in primary breast carcinomas and their axillary lymph node metastases.
Pathol Res Pract 1994 Aug, 190(7): 675-81
93. HARRIS JR, Hellmann S, Canellos GP, Fischer B:
Cancer of the breast. In: DE VITA, V.T., Hellmann, S., Rosenberg, St.A. (Eds.):
Cancer, principles & practice of oncology. 2. Ed. S. 1119-1177. J.B. Lippincott Company, Philadelphia (1985).
94. HARTVEIT F, Tangen M, Hartveit E:
Side and Survival in Breast Cancer.
Oncology 1984, (41)149:149-154
95. HARVEY JM, deKlerk NH, Sterrett GF:
Histological grading in breast cancer: interobserver agreement, and relation to other prognostic factors including ploidy.
Pathology 1992, 24:63-68

96. HENSON DE, Fielding P, Grignon DJ, Page DL, Hammond ME, Nash G, Pettigrew NM, Gorstein F and RVP Hutter:
College of American Pathologists Conference XXVI on clinical Relevance of prognostic Markers in solid Tumors.
Arch Pathol Lab Med 1995 Dec, Vol 119:1109-1112
97. HEDLEY DW
DNA cytometry consensus conference. DNA flow cytometry and breast cancer.
Breast Cancer Res Treat 1993, 28:51-53
98. HEDLEY DW, Rugg CA, Gelber RD
Association of DNA index and S- phase fraction with prognosis of nodes positive early breast cancer.
Cancer Res 1987, 47:4729-4735
99. HELLEMANS P, van-Dam PA, Weyler J, van-Oosterom AT, Buytaert P, van Marck E:
Prognostic value of bcl-2 expression in invasive breast cancer.
Br J Cancer 1995 Aug, 72(2):354-60
100. HILDENBRAND R, Dilger I, Horlin A, Stutte HJ:
Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer.
Pathol Res Pract 1995 Jun, 191(5):403-9
101. HOLFORD T R, Roush GC, McKay LA:
Trends in female breast cancer in Connecticut and the United States.
J Clin Epidemiol 1991, 44:29-39
102. HOLLAND R, Veling SHJ, Mravunac M, Driks JHCL:
Histologic Multifocality of Tis, T1-2 Breast Carcinomas. Implications for Clinical Trials of Breast-Conserving Surgery.
Cancer 1995, 56:979-629
103. HOPTON DS, Thorogood J, Clayden AD, MacKinnon D:
Histological grading of breast cancer; significance of grade on recurrence and mortality.
Eur J Surg Oncol 1989, 15:25-31
104. HORIGUCHI J, Iino Y, Takei H, Morishita Y, Nakajima T:
Expression of proliferating cell nuclear antigen in invasive ductal carcinoma of the breast.
Jpn J Clin Oncol 1994 Apr, 24(2): 79-84
105. HUHNS FO, Stock G:
Zur Frage eingeschränkter sowie begrenzter Behandlungsmöglichkeiten von Mamma-Carcinomen. Befunddokumentation an 400 Operationspräparaten.
Arch Gyn 1977, 244: 341-342
106. HURLIMANN J, Gebhard S, Gomez F:
Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas.
Histopathology 1993 Sep, 23(3):239-48

107. HUTTER RVP:
Pathological parameters useful in predicting prognosis for patients with breast cancer.
In: *The breast*. Washington, DC: International Academy of Pathology, No.25 1984,175-185
108. IBRAHIM NB, Padfield CJ, Rees EJ, Wilson Y, Cawthorn SJ:
Immunocytochemistry in the assessment of pS2 protein expression in fine needle aspiration cytology from breast carcinoma.
Cytopathology 1993, 4(6):323-30
109. IKEDA T, Enomoto K, Wada K, Yoneyama K, Furukawa J, Watanabe Y, Mukai M and M Kitajima:
Frozen-Section-Guided Breast-Conserving Surgery: Implications of Diagnosis by Frozen Section as a Guide to Determining the Extent of Resection.
Jpn J Surg 1997, 27:207-212
110. ISOLA J, Weitz S, Visakorpi T, Holli K, Shea R, Khabbaz N, Kallioniemi OP:
Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.
J Clin Oncol 1993 Jan, 11(1):36-43
111. JANICKE F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, Graeff H:
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.
Breast Cancer Res Treat 1993, 24(3): 195-208
112. JOENSUU H, Pylkkanen L, Toikkanen S:
Bcl-2 protein expression and long-term survival in breast cancer.
Am J Pathol 1994 Nov, 145(5):1191-1198
113. KALLIONIEMI OP, Blanco G, Alavaikko M, Hietanen T, Mattila J, Lauslahti K, Koivula T:
Tumour DNA ploidy as an independent prognostic factor in breast cancer.
Br J Cancer 1987, 56:637-642
114. KAMAKURA T, Akazawa K, Nomura Y, Sugimachi K, Nose Y:
Poor prognosis of lower quadrant breast carcinoma.
Journal of Surgical Oncology 1996, 61:295-299
115. KAMBOURIS AA:
Axillary node metastases in relation to size and location of breast cancers: Analysis of 147 Patients.
The American Surgeon 1996 Jul, Vol. 62, No. 7: 519-524
116. KIDA N, Yoshimura T, Takahashi H, Nagao S, Nozawa Y, Furukawa Y, Mori K, Hayashi K:
Estrogen-inducible pS2 protein is not the key regulatory component in the proliferation of human breast cancer cells (MCF-7).
Eur J Biochem 1993 Aug 1, 215(3): 671-676

117. KISTER SJ, Sommers SC, Haagenson CD, Friedell GH, Cooley E, Varma A:
Nuclear grade and sinus histiocytosis in cancer of the breast.
Cancer 1969, 23: 570-575
118. LANZAFAME S, Magro G, Broggi B:
Minimal breast cancer: analysis of proliferative activity using a monoclonal antibody to
proliferating cell nuclear antigen (PCNA) and its relationship to histological grade and
prognosis.
Pathologica 1994 Apr 86(2):150-156
119. LASH RH, Bauer TW, Hermann RE, Esselstyn CB:
Partial mastectomy: Pathology and prognosis.
Hum Pathol 1986,17:813-822
120. LAURIA R, Perrone F, Carlomagno Ch, De Laurentiis M, Morabito A, Gallo C,
Varriale E, Pettinato G, Panico L, Petrella G, Bianco AR, De Placido S:
The prognostic value of lymphatic and blood vessel invasion in operable breast cancer.
Cancer 1995, 76: 1772-1778
121. LEDOUSSAL V, Tubiana-Hulin M, Friedman S, Hacene K, Spyrtatos F, Brunet M:
Prognostic value of histologic grade/nuclear components of Scarff-Bloom-Richardson
(SBR).A improved score modification based on a multivariate analysis of 1262 invasive
ductal carcinomas.
Cancer 1989,64:1914-1921
122. LIPPONEN P, Pietilainen T, Kosma VM, Aaltomaa S, Eskelinen M, Syrjanen K :
Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carci-
nomas with favourable prognosis.
J Pathol 1995 Sep, 177(1): 49-55
123. MAEHLE BO, Skjaerven R:
Prediction of prognosis in axillary lymph node positive breast cancer patients: a sta-
tistical study.
Br J Surg 1984 June, Vol. 71: 459-462
124. MACMAHON B, List ND, Eisenberg H:
Relationship of survival of breast cancer patients to parity and menopausal status.
In: Forrest AP,Kunkler PB,eds. Prognostic factors in
breast cancer. Edinburgh,Livingstone,1968,56-64
125. MANSOUR EG, Ravdin PM, Dressler L:
Prognostic factors in early breast carcinoma.
Cancer 1994 Jul 1, 74(1 Suppl):381-400
126. MARTINAZZI M, Crivelli F, Zampatti C, Martinazzi S:
Relationships between epidermal growth factor receptor (EGF-R) and other predictors
of prognosis in breast carcinomas. An immunohistochemical study.
Pathologica 1993 Nov-Dec, 85(1100): 637-44
127. MARQUES LA, Franco ELF, Torloni H:
Independent prognostic value of laminin receptor expression in breast cancer survival.
Cancer Res 1990 ,(50):1479-1483

128. MCDIVITT RW, Stone KR, Craig RB, Meyer JS:
A comparison of human breast cancer cell kinetics measured by flow cytometry and thymidine labeling.
Lab Invest 1985, 52:287-291
129. MCDIVITT RW, Stewart FW, Berg JW:
Tumor of the breast.
Atlas of tumor pathology. 1968 2nd Ser., Fasc2, Washington DC, AFIB
130. MCDIVITT RW, Stewart FW, Berg JW:
Tubular carcinoma of the breast.
Am J Surg Pathol 1982, 6:401-411
131. MCGUCKIN MA, Walsh MD, Hohn BG:
Prognostic significance of MUC1 epithelial mucin expression in breast cancer.
Hum Pathol 1995, 26: 432-439
132. McGUIRE WL, Tandon AK, Allred DC, Chamness GC, Clark GM :
How to use prognostic factors in axillary node-negative breast cancer patients.
J Natl Cancer Inst 1990, 82:1006-1012
133. McGUIRE WL, Clark GM:
Prognostic factors and Treatment decisions in axillary-node-negative breast cancer.
The New England Journal of Medicine 1992 June 25, Vol.326, No.26:1756-1761
134. MERKEL DE, Winchester DJ, Goldschmidt RA, August CZ, Wruck DM, Rademaker AW:
DNA flow-cytometry and pathologic grading as prognostic guides in axillary lymph node-negative breast Cancer.
Cancer 1993, 72: 1926-1932
135. MEYER JS, Friedman E, McCrate MM, Bauer WC:
Prediction of early course of breast carcinoma by thymidine labeling.
Cancer 1983, 51:1879-1886
136. MICCOLI P, Migliori E, Spinelli C, Squartini F, Roncella M, Rossi G and Iaconi P:
Correlation between 5-year survival of T1-T2 N0 breast cancer and some pathologic parameters.
Eur J Surg Oncol 1988,14: 217-219
137. MITZE M, Weikel W, Brumm C, Lippold R, Knapstein PG:
Einfluß der Proliferationsrate auf den Krankheitsverlauf von nodalnegativen Mammakarzinomen.
Geburtshilfe Frauenheilkd 1995, 55: 299-305
138. MOOT SK, Peters GN, Cheek JH:
Tumor hormone receptor status and recurrences in premenopausal node negative breast carcinoma.
Cancer 1987,60: 382-385
139. MORIKI T, Takahashi T, Tanioka F, Yamane T, Hara H:
Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein.
Pathol Res Pract 1995 Nov; 191(11): 1122-32

140. MÜLLER H, Remberger S, Stutte HJ:
Die P-Glykoproteinexpression als Ausdruck der multi-drug-resistance (MDR), Tumorproliferation, tumorassoziierte inflammatorische Zellen und Prognosefaktoren im invasiven duktalem Mammakarzinom.
Verh Dtsch Ges Path 1990, 74:597
141. MUSS HB, Kute TE, Case LD, Smith LR, Booher C, Long R, Kammire L, Gregory B, Brockschmidt JK:
The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer.
Cancer 1989, 64:1894-1900
142. NAGEL GA, Holtkamp W, Wander HE:
Biologische und klinische Prognosefaktoren metastasierender Mammakarzinome.
In: KUBLI F, Nagel GA, Kadach U, Kaufmann M (Hrsg.): Neue Wege in der Brustkrebsbehandlung. Aktuelle Onkologie 8, S. 91-105. W. Zuckschwerdt Verlag, München, Bern, Wien (1983)
143. NAKOPOULOU L, Lazaris AC, Baltas D, Giannopoulou I, Kavantzas N, Tzonou A:
Prognostic evaluation of oestrogen-regulated protein immunoreactivity in ductal invasive (NOS) breast cancer.
Virchows Arch 1995, 427(1):33-40
144. NAMER M, Ramaioli A, Hery M, Ferrero JM:
Facteurs pronostiques et strategie therapeutique du cancer du sein.
Rev Prat 1998 Jan 1, 48(1): 45-51
145. NAUKKARINEN A, Syrjänen K:
Quantitative immunohistochemical analysis of mononuclear infiltrates in breast carcinomas-correlation with the differentiation.
J Pathol (1990),160:217-222
146. NARITA M, Nakao K, Ogino N, Nakahara G, Onishi A, Tsujimoto M:
Independent Prognostic Factors in Breast Cancer Patients.
Am J Surg 1998, Vol 175:73-75
147. NARITA T, Funahashi H, Satoh Y, Takagi H:
Proliferating cell nuclear antigen immunostaining in breast cancer and its relation to prognosis.
Jpn J Clin Oncol 1993 Feb, 23(1): 20-25
148. NASSER IA, Lee AKC, Bosari S, Saganich R, Heatly G, Silvermann ML:
Occult axillary lymph node metastases in "node-negative" breast carcinoma.
Hum Pathol 1993, 24 :950-957
149. NATIONAL CANCER INSTITUTE:
Cancer statistics review 1973-1986. Including a report on the status of cancer control
United States Department of Health and Human Services NIH 89, (1989)

150. NEMOTO T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP:
Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons.
Cancer 1980, 45:2917-2924
151. NIXON AJ, Neuberg D, Hayes DF, Gelman R, Conolly JL, Schnitt S, Abner A, Recht A, Vicini F, Harris JR:
Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer.
J Clin Oncol 1994, Vol 12 No 5:888-894
152. NOGUCHI S, Koyama H, Kasugai T, Tsukuma H, Tsuji N, Tsuda H, Akiyama F, Motomura K, Inaji H:
A case control study on risk factors for local recurrences or distant metastases in breast cancer patients treated with breast-conserving therapy.
Oncology 1997,54:468-474
153. NORRIS HJ, Austin RM:
Overview of prognostic factors in mammary carcinoma.
Breast Dis Breast 1985,11/4: 9-11, 15-17
154. ÖFNER D, Hittmaier A, Marth C:
Relationship between quantity of silver stained nucleolar organizer regions associated proteins (Ag-NORSs) and populations doubling time in ten breast cancer cell lines.
Pathol Res Pract 1992, 188: 742-746
155. ÖFNER D, Bankvalvi A, Riehemann K, Böcker W, Schmidt KW:
Standardisierte AgNOR-Färbemethode für formalinfixiertes und paraffineingebettetes Material.
Pathologie 1994, 15:226-230
156. ORDONEZ NG, Brooks T, Thompson S, Batsakis JG:
Use of Ulex europaeus agglutinin I in the identification of lymphatic or blood vessel invasion in previously stained microscopic slides.
Am J Surg Pathol 1987,11:543-550
157. PARL FF, Dupont WD:
A retrospective cohort study of histological risk factors in breast cancer patients.
Cancer 1982, 50:2410-2416
158. PARHAM DM, Robertson AJ, Brown RA:
Morphometric analysis of breast carcinoma: association with survival.
J Clin Pathol 1988, 41/2:173-177
159. PEDERSEN L, Zedeler K, Holck S, Schiodt T, Mouridsen HAT:
Medullary carcinoma of the breast. Prevalence and prognostic importance of classical risk factors in breast cancer.
Eur J Cancer 1995, Vol 31A Nos 13/14:2289-2295
160. PEER G, Verbeek C, Mravunac L, Hendriks F, Holland B:
Prognosis of younger and older patients with early breast cancer.
British Journal of Cancer 1996,73: 382-385

161. PINDER SE, Ellis IO, Galea M, O'Rourke S, Blamey RW, Elston CW:
Pathological prognostic factors in breast cancer. III. Vascular invasion: Relationship with recurrence and survival in a large study with long-term follow-up.
Histopathology 1994, 24:41-47
162. PIRINEN R, Lipponen P, Syrjanen K:
Expression of epidermal growth factor receptor (EGFR) in breast cancer as related to clinical, prognostic and cytometric factors.
Anticancer Res 1995 Nov-Dec, 15(6B):2835-40
163. PLATTHY G, Dinstl K, Härb HJ und Fischer R:
88. Lokalrezidive nach Operation wegen Mammakarzinom und ihre Beziehung zum Primäreingriff.
Langenbecks Arch. Chir 1986, 369 Kongressbericht:437-439
164. POREMBA C, Bankvalvi A, Dockhorn-Dworniczak B:
Das Tumorsuppressorgen p53.
Pathologie 1996, 17:181-188
165. PRECHTEL K, Prechtel D:
Breast carcinoma and breast saving therapy - a critical comment from the viewpoint of the Pathologist.
Geburtshilfe Frauenheilkd 1996 Apr, 56(4):184-189
166. RAAF HN, Jacobsen DW, Savon S, Green R:
Serum transferrin receptor level is not altered in invasive adenocarcinoma of the breast .
Am J Clin Pathol 1993 Mar, 99(3): 232-237
167. RACCA S, Conti G, Pietribiasi F, Stramignoni D, Tampellini M, Valetto MR, Ghezzi F, Di-Carlo F:
Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer.
Int J Biol Markers 1995 Apr-Jun, 10(2):87-93
168. RANK F, Dombernowsky P, Bang Jespersen NC, Pedersen BV, Kreiding H.:
Histologic malignancy grading of invasive ductal breast carcinoma: A regression analysis of Prognostic factors in low risk carcinomas from a multicenter trial.
Cancer 1987,60:1299-1305
169. RAUSCHECKER HF, Sauerbrei W, Gatzemeier W, Sauer R, Schauer A, Schmoor C and Schumacher M:
Eight-year Results of a Prospective Non-randomised Study on therapy of Small Breast Cancer.
Eur J Cancer 1998, Vol 34 No3:315-323
170. REMBERGER R:
Die Bedeutung der Immunhistochemie zur Frage der Frühinvasion maligner Tumoren.
In: Kindermann G., Lampe B. (Hrsg.) Immunhistochemische Diagnostik gynäkologischer Tumoren.
Thieme, Stuttgart, New-York (1992) S.87-93

171. RENTON SC, Gazet JC, Ford HT, Corbishley C and Sutcliffe R:
The importance of the resection margin in conservative surgery for breast cancer.
Eur J Surg Oncol 1996, 22: 17-22
172. ROCHEFORT H:
Estrogenes, cathepsine D et metastases dans les cancers du sein et de l'ovaire: invasion ou proliferation?
C R Sc Soc Biol Fil.1998, 192(2): 241-51
173. ROMAIN S, Spyrtos F, Laine-Bidron C, Bouchet C, Guirou O, Martin PM, Oglobine J, Magdelenat H:
Comparative study of four extraction procedures for urokinase type plasminogen activator and plasminogen activator inhibitor-1 in breast cancer tissues.
Eur J Clin Chem Clin Biochem 1995 Sep, 33(9): 603-608
174. ROSEN PP, Saigo PE, Braun DW, Weathers E, Fracchia AA, Kinne DW:
Axillary micro- and macrometastases in breast cancer. Prognostic significance of tumor size.
Ann Surg 1981,194:585-591
175. ROSEN PP:
The pathological classification of human mammary carcinoma: past, present and future.
Ann Clin Lab Sci 1979, 9:144-156.
176. ROSEN PP, Saigo PE, Braun DWJr, Weathers E, DePalo A:
Predictors of recurrence in stage I (T1N0M0) breast carcinoma.
Ann Surg 1981, 193:15-25
177. ROSEN PP, Saigo PE, Braun DW Jr, Weathers E, Kinne DW:
Prognosis in Stage II (T1N1M0) breast cancer.
Ann Surg 1981,194:576-584
178. ROSES DF, Bell DA, Flotte TJ, Taylor R, Ratech H, Dubin N:
Pathologic predictors of recurrence in stage I (T1N0M0) breast cancer.
Am J Clin Pathol 1982, 78: 817-820
179. ROSNER D, Lane WW:
Should all patients with node-negative breast cancer receive adjuvant therapy?
Cancer 1991, 68:1482-1494
180. ROCHEFORDIÉRE De La A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR, Durand JC, Pouillart P, Magdelenat H, Fourquet A:
Age as prognostic factor in premenopausal breast carcinoma.
The Lancet 1993, Vol 341 No 8852: 1039-1043
181. RUDAS M, Gnant MF, Mittlbock M, Neumayer R, Kummer A, Jakesz R, Reiner G, Reiner A:
Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis.
Breast Cancer Res Treat 1994, 32(2): 165-175

182. SAPHIR O, Amromin GD:
Obscure axillary lymph-node metastasis in carcinoma of the breast.
Cancer 1948; 1: 238-241
183. SASANO H, Nagura H, Havada N:
Immunolocalization of aromatase and other stereogenetic enzymes in human breast cancer.
Hum Pathol 1994, 25:530-535
184. SAUER T, Naess O:
Expression of the pS2 protein and correlation with estrogen receptor status in fine-needle aspirates from breast carcinomas.
Diagn Cytopathol 1994, 11(2):165-7
185. SCHAUER A, Brehler R und Bergholz M:
86. Morphologische Kriterien für die brusterhaltende Chirurgie.
Langenbecks Arch Chir 1987, 369 (Kongreßbericht 1986) 427-436
186. SCHMID KW, Ellis IO, Gee JMW:
Presence and possible significance of immunocytochemically demonstrable Metallothionein over-expression in primary invasive ductal carcinoma of the breast.
Virchows Arch A Pathol Anat 1993, 422:153-159
187. SCHNEIDER J, Romero H:
Correlation of P-glycoprotein overexpression and cellular prognostic factors in formalin-fixed, paraffin-embedded tumor samples from breast cancer patients.
Anticancer Res 1995 May-Jun, 15(3):1117-1121
188. SCHNITT SJ, Connolly JL, Harris JR, Hellman S, Chen RB:
Pathologic predictors of early local recurrences in Stage I and II breast cancer treated by primary radiation therapy.
Cancer 1984, 53:1049-1057
189. SCHNITT SJ, Abner A, Gelman R, Connolly JL, Recht A, Duda RB, Eberlein TJ, Mayzel K, Silver B, Harris JR:
The Relationship between Microscopic Margins of Resection and the Risk of Local Recurrence in Patients with Breast Cancer treated with Breast-Conserving Surgery and Radiation Therapy.
Cancer 1994, 74:1746-1751
190. SCHNÜRCH HG, Lange C, Bender HG:
Vier histologische Differenzierungsgrade beim Mammakarzinom ?
Pathologie 1989, 10:39-42
191. SCHÖNBORN I, Mingiullon N, Möhner M, Ebeling K:
Die Bedeutung der PCNA-Proliferationsfraktion für das Überleben beim Mammakarzinom.
Pathologie 1993, 14:307-312

192. SCHUMACHER M, Schmoor C, Sauerbrei W, Schauer A, Ummenhofer L, Gatzemeier W, Rauschecker H:
The prognostic effect of histological tumor grade in node-negative breast cancer patients.
Breast Cancer Res Treat 1993, 25:235-245
193. SEARS HF, Janus C, Levy W, Hopson R, Creech R, Grotzinger P:
Breast cancer without axillary metastases.
Cancer 1982, 50:1820-1827
194. SHAHEEN RM, Miseljic S, Wiehle RD, Wittliff JL:
Relation between cathepsin D expression and other prognostic factors in breast carcinomas.
Clin Chem 1995 Nov, 41(11) 1585-1591
195. SINN HP, Haag D, Ehemann V, Magener A, Goerttler K, Bastert G und Otto HF:
DNA-Zytometrie beim Mammakarzinom.
Pathologe 1997, 18: 19-26
196. SOUBEYRAN I, Wafflart J, Bonichon F, de-Mascarel I, Trojani M, Durand M, Avril A, Coindre JM :
Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases.
Breast Cancer Res Treat 1995 May, 34(2): 119-28
197. SPEISER P, Stolzlechner J, Haider K, Heinzl H, Jakesz R, Pecherstorfer M, Rosen H, Sevelda P, Zeilliger R:
pS2 protein status fails to be an independent prognostic factor in an average breast cancer population.
Anticancer Res 1994 Sep-Oct, 14(5B):2125-2130
198. STEGNER HE:
Die Rolle des Pathologen in der stadiengerechten Therapie des Mammakarzinoms.
Pathologe 1982, 3:137-148
199. STOSIEK U, Breitbach GP, Wolfmüller H:
Zur prognostischen Wertigkeit morphologischer Kriterien beim Mammakarzinom.
Pathologe 1984, 5: 86-89
200. STOISEK P, Gerber B, Kasper M:
Zur prognostischen Bedeutung von Mikrometastasen in axillären Lymphnoten beim Mammakarzinom.
Pathologe 1996, 17: 433-439
201. SWEEP CG, Geurts-Moespot J, Grebenschikov N, de-Witte JH, Heuvel JJ, Schmitt M, Duffy MJ, Janicke F, Kramer MD, Foekens JA, Brunner N, Brugal G, Pedersen AN, Benraad TJ:
External quality assessment of trans-european multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
Br J Cancer 1998 Dec, 78(11):1434-1441

202. SWENSON KK, Decher L, Haselow R. und J.B. Farrell:
Prognostic Factors after conservative surgery and radiation therapy for early stage breast cancer.
Am J Clin Oncol (CCT) 1998, 21 (2):111-116
203. TANDON AK, Clark GM, Chamness GC :
Cathepsin D and prognosis in breast cancer .
N Engl J Med 1990, 322: 297-302
204. THOMAS M, Noguchi M, Kitagawa H, Kinoshita K, Miyazaki I:
Poor prognostic value of proliferating cell nuclear antigen labelling index in breast carcinoma.
J Clin Pathol 1993 Jun; 46(6): 525-8
205. THOMPSON AM, Hawkins RA, Elton RA, Steel CM, Chetty U, Carter DC:
pS2 is an independent factor of good prognosis in primary breast cancer.
Br J Cancer 1993 Jul, 68(1): 93-96
206. TNM - Klassifikation maligner Tumoren
Hrsg.: Wittekind C, Wagner G
5.Aufl. 1997 Springer Verlag Heidelberg.
207. TOI M, Nakamura T, Mukaida H: .
Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer.
Cancer 1990, 65: 1980-1984
208. TSANGARIS TN, Knox SM, Cheek JH:
Tumor hormone receptor status and recurrences in premenopausal patients with node-negative breast carcinoma.
Cancer 1992, 69:984-987
209. TSUCHIYA A, Abe R, Kanno M, Ohtake T, Fukushima T , Nomizu T, Kimijima I:
Role of age as a prognostic factor in breast cancer.
Jpn J Surg 1997, 27: 213-216
210. VAN DE VELDE CJH, Gallager HS, Giacco GG:
Prognosis in node-negative breast cancer.
Breast Cancer Res Treat 1986, 8:189-196
211. VERONESI U, Salvadori B, Luini A:
Breast Conservation is a safe method in patients with small cancer of the breast.
Eur J Cancer 1995,31A:1574-1579
212. WALDMANN FM, Chew K, Ljung BM:
A comparison between bromodeoxyuridine and 3H-thymidine labeling in human breast tumors.
Mod Pathol 1991, 4:718-722
213. WAPNIR JL, Bancila E, Devereux DF, Greco RS:
Residual Tumor and breast Biopsy Margins.
Breast Dis 1989, 2:81-86

214. WEIDNER N, Moore DH, Ljung BM:
Correlation of bromdeoxyuridine (BrdU) labeling of breast carcinoma cells with mitotic figure content and tumor grade.
Am J Surg Pathol (1993) 17: 987-994
215. WITZIG TE, Ingle JN, Cha SS, Schaid DJ, Tabery RJ, Wold LE, Grant C, Gonchoroff NJ, Katzmann JA:
DNA ploidy and the percentage of cells in S-phase as prognostic factors for women with lymph node negative breast cancer.
Cancer 1994, 74:1752-1761
216. WORLD HEALTH ORGANIZATION
The World Health Organization histological typing of breast tumors -second edition.
Am. J. Clin. Pathol. 1982, 78:806-816
217. WRBA F, Ritzinger E, Reiner A, Holzner JH:
Transferrin receptor (TrfR) expression in breast carcinoma and possible relationship to prognosis.
Virchows Arch A (Pathol Anat) 1986, 410: 69-73
218. YAMASHITA J, Ogawa M, Sakai K:
Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer.
Surgery 1995 Jun, 117(6): 601-608
219. ZIPPEL HH, Kaiser R, Citoler P:
Indikationen zur subkutanen Mastektomie beim Mammakarzinom.
Arch Gyn 1977, 244: 340-341